APA (7th ed.) Citation

CS, F., K, S., S, K., E, W., A, G., M, K., . . . JE, N. (2025). Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. Addiction science & clinical practice, 20(1), 89. https://doi.org/10.1186/s13722-025-00618-2

Chicago Style (17th ed.) Citation

CS, Freet, et al. "Efficacy of the GLP-1 Receptor Agonist, Semaglutide, in Abstinence from Illicit and Nonprescribed Opioids in an Outpatient Population with OUD: A Randomized, Double-blind, Placebo-controlled Clinical Trial Protocol." Addiction Science & Clinical Practice 20, no. 1 (2025): 89. https://doi.org/10.1186/s13722-025-00618-2.

MLA (9th ed.) Citation

CS, Freet, et al. "Efficacy of the GLP-1 Receptor Agonist, Semaglutide, in Abstinence from Illicit and Nonprescribed Opioids in an Outpatient Population with OUD: A Randomized, Double-blind, Placebo-controlled Clinical Trial Protocol." Addiction Science & Clinical Practice, vol. 20, no. 1, 2025, p. 89, https://doi.org/10.1186/s13722-025-00618-2.